| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2801788101013 | 178810101 | GLOPIR F.C.TAB 10MG/TAB BTX50(BLIST5X10) | 1.52 | 1.59 | 2.19 |
| 05/2018 | 2801788102010 | 178810201 | GLOPIR PR.TAB 20MG/TAB BTX30(BLIST3X10) | 1.85 | 1.94 | 2.67 |
For the management of vasospastic angina, chronic stable angina and hypertension.
Nifedipine inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. The decrease in intracellular calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Symptoms of overdose include dizziness, drowsiness, nausea, severe drop in blood pressure, slurred speech, and weakness. LD<sub>50</sub>=494 mg/kg (orally in mice); LD<sub>50</sub>=1022 mg/kg (orally in rats)
Rapidly and fully absorbed following oral administration.
2 hours
Nifedipine is extensively metabolized to highly water-soluble, inactive metabolites accounting for 60 to 80% of the dose excreted in the urine. The remainder is excreted in the feces in metabolized form, most likely as a result of biliary excretion.